Everyone wants to live here. Photo by Kevin Hernandez on Unsplash

Start spreading the news: Houston will eclipse New York City as the 2nd biggest metro area by the year 2100, a new report predicts.

An analysis by moving services site moveBuddha published June 22 says Houston's population could swell to 31.38 million people in the next 77 years.

Based on current population and migration trends, in fact, America’s three biggest metropolitan areas by 2100 will be Dallas-Fort Worth (No. 1), Houston (No. 2), and Austin (No. 3), replacing New York, Los Angeles, and Chicago as the country’s most populous metros, the report predicts.

Dallas-Fort Worth's population is estimated to grow to 33.91 million, and Austin's is projected to jump to 22.29 million.

"The future of America may lie in Texas," the report's author says.

The latest data from the U.S. Census Bureau says Houston-The Woodlands-Sugar Land is currently the No. 5 biggest metro in the country with a population of more than 7.2 million and a 10-year growth rate of about 20 percent.

Houston-The Woodlands-Sugar Land had the second highest numeric increase in population between 2021 and 2022 of any U.S. metro (124,281 residents), following Dallas-Fort Worth-Arlington (170,396 residents), according to the Census Bureau.

There are some risks to continued population booms, including the effects of climate change, moveBuddha points out. While heat will be a major issue, there are much more dangerous possibilities.

"The bigger threat may be more destructive hurricanes from off the Gulf of Mexico," the report's author says. "Hurricane Harvey devastated Houston in 2017, and major storms like that could become more common. A historic flood also nailed the city in 2019. Planning for a future of these climate-induced threats will be critical for Houston."

The study also comes with an obvious caveat: no one is sure what the future looks like in terms of population growth. Academics, scientists, and futurists alike haven't been able to agree on population predictions. Climate change isn't just a risk for Houston, but for the entire world, the report reminds.

"According to one GDP projection through 2099, over three-quarters of U.S. counties will suffer economically because of climate damage," the report says. "That could be from everything from heat-related deaths to sea-level rise to increased natural disasters... But if global warming is held in check, Texas may be America’s haven in 2100. New technologies may help us adapt to extreme weather and heat."

According to the report, the top 10 largest metros and their populations by 2100 will be:

  • No. 1 – Dallas-Fort Worth (33,907,275)
  • No. 2 – Houston (31,384,122)
  • No. 3 – Austin (22,293,980)
  • No. 4 – Phoenix (22,271,212)
  • No. 5 – New York City (20,810,467)
  • No. 6 – Atlanta (18,370,497)
  • No. 7 – Los Angeles (15,502,798)
  • No. 8 – Washington-Arlington, D.C.-Virginia (14,972,830)
  • No. 9 – Orlando (14,172,727)
  • No. 10 – Miami (13,779,843)
These projections were calculated using census data from 2010 and 2020, using annual compound and 10-year population growth rates for U.S. metro areas with over 250,000 people. The study then hypothesized the annual compound growth rates between 2020 and 2100 to find 2100's estimated population numbers for the same cities.The full report and its methodology can be found on movebuddha.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”